Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $73,246.50 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 3,690 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded down $0.60 during trading hours on Monday, hitting $19.11. 324,693 shares of the company were exchanged, compared to its average volume of 650,943. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.59 and a beta of 2.14. Nurix Therapeutics, Inc. has a one year low of $7.92 and a one year high of $29.56. The business's 50-day simple moving average is $20.05 and its two-hundred day simple moving average is $22.37.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank raised its holdings in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. Quarry LP boosted its position in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after acquiring an additional 2,435 shares during the period. International Assets Investment Management LLC grew its stake in shares of Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock worth $101,000 after purchasing an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company's stock valued at $168,000 after purchasing an additional 1,312 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. UBS Group assumed coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $35.00 price objective on the stock. BTIG Research initiated coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $35.00 price objective for the company. HC Wainwright raised their target price on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Stephens reaffirmed an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Needham & Company LLC cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating on the stock in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.12.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.